{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:41:05Z","timestamp":1791862865434,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2TR002490"],"award-info":[{"award-number":["KL2TR002490"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01DK110023-01A1"],"award-info":[{"award-number":["1R01DK110023-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00467-021-04965-5","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T17:04:42Z","timestamp":1615395882000},"page":"2349-2360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes\u2014a Pediatric Nephrology Research Consortium study"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9575-8356","authenticated-orcid":false,"given":"Melissa","family":"Muff-Luett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keia R.","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Engen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima S.","family":"Zahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Wenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl L.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Ingraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Winnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy E.","family":"Hunley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan G.","family":"Kiessling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Seamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Woroniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianzhou","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiodun A.","family":"Omoloja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Kizilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Mansuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Kallash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley K.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarak","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla M.","family":"Nester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"key":"4965_CR1","first-page":"1017","volume":"3","author":"M Kaplan","year":"2002","unstructured":"Kaplan M (2002) Eculizumab (Alexion). Curr Opin Investig Drugs 3:1017\u20131023","journal-title":"Curr Opin Investig Drugs"},{"key":"4965_CR2","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256\u20131264. https:\/\/doi.org\/10.1038\/nbt1344","journal-title":"Nat Biotechnol"},{"key":"4965_CR3","doi-asserted-by":"publisher","unstructured":"Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace GH, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit SW, Mizuno K, Warren M, Davies SM (2020) Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with eculizumab. Blood. https:\/\/doi.org\/10.1182\/blood.2019004218","DOI":"10.1182\/blood.2019004218"},{"key":"4965_CR4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1053\/j.ajkd.2009.08.011","volume":"55","author":"JC Davin","year":"2010","unstructured":"Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T (2010) Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 55:708\u2013711. https:\/\/doi.org\/10.1053\/j.ajkd.2009.08.011","journal-title":"Am J Kidney Dis"},{"key":"4965_CR5","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1111\/j.1600-6143.2009.02817.x","volume":"9","author":"V Chatelet","year":"2009","unstructured":"Chatelet V, Fremeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B (2009) Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 9:2644\u20132645. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02817.x","journal-title":"Am J Transplant"},{"key":"4965_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMc0809959","volume":"360","author":"RA Gruppo","year":"2009","unstructured":"Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 360:544\u2013546. https:\/\/doi.org\/10.1056\/NEJMc0809959","journal-title":"N Engl J Med"},{"key":"4965_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJMc0808527","volume":"360","author":"J Nurnberger","year":"2009","unstructured":"Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360:542\u2013544. https:\/\/doi.org\/10.1056\/NEJMc0808527","journal-title":"N Engl J Med"},{"key":"4965_CR8","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.2215\/CJN.01090209","volume":"4","author":"CJ Mache","year":"2009","unstructured":"Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E (2009) Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:1312\u20131316. https:\/\/doi.org\/10.2215\/CJN.01090209","journal-title":"Clin J Am Soc Nephrol"},{"key":"4965_CR9","doi-asserted-by":"publisher","first-page":"e003573","DOI":"10.1136\/bmjopen-2013-003573","volume":"3","author":"J Rathbone","year":"2013","unstructured":"Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A (2013) A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open 3:e003573. https:\/\/doi.org\/10.1136\/bmjopen-2013-003573","journal-title":"BMJ Open"},{"key":"4965_CR10","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","volume":"125","author":"R Cofiell","year":"2015","unstructured":"Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ (2015) Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 125:3253\u20133262. https:\/\/doi.org\/10.1182\/blood-2014-09-600411","journal-title":"Blood"},{"key":"4965_CR11","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s00467-011-1989-4","volume":"26","author":"S Tschumi","year":"2011","unstructured":"Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD (2011) Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol 26:2085\u20132088. https:\/\/doi.org\/10.1007\/s00467-011-1989-4","journal-title":"Pediatr Nephrol"},{"key":"4965_CR12","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169\u20132181. https:\/\/doi.org\/10.1056\/NEJMoa1208981","journal-title":"N Engl J Med"},{"key":"4965_CR13","unstructured":"Soliris (eculizumab) full prescribing information (2011) Alexion Pharmaceuticals, Cheshire, CT"},{"key":"4965_CR14","unstructured":"Soliris (eculizumab) full prescribing information (2017) Boston, MA"},{"key":"4965_CR15","doi-asserted-by":"publisher","first-page":"e27913","DOI":"10.1002\/pbc.27913","volume":"66","author":"U Mahat","year":"2019","unstructured":"Mahat U, Matar RB, Rotz SJ (2019) Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: a review of current evidence. Pediatr Blood Cancer 66:e27913. https:\/\/doi.org\/10.1002\/pbc.27913","journal-title":"Pediatr Blood Cancer"},{"key":"4965_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nrneph.2012.196","volume":"8","author":"H Trachtman","year":"2012","unstructured":"Trachtman H, Austin C, Lewinski M, Stahl RA (2012) Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 8:658\u2013669. https:\/\/doi.org\/10.1038\/nrneph.2012.196","journal-title":"Nat Rev Nephrol"},{"key":"4965_CR17","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/ndt\/gft470","volume":"29","author":"Y Delmas","year":"2014","unstructured":"Delmas Y, Vendrely B, Clouzeau B, Bachir H, Bui HN, Lacraz A, Helou S, Bordes C, Reffet A, Llanas B, Skopinski S, Rolland P, Gruson D, Combe C (2014) Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 29:565\u2013572. https:\/\/doi.org\/10.1093\/ndt\/gft470","journal-title":"Nephrol Dial Transplant"},{"key":"4965_CR18","doi-asserted-by":"publisher","first-page":"e1000","DOI":"10.1097\/MD.0000000000001000","volume":"94","author":"L Pape","year":"2015","unstructured":"Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T (2015) Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine (Baltimore) 94:e1000. https:\/\/doi.org\/10.1097\/MD.0000000000001000","journal-title":"Medicine (Baltimore)"},{"key":"4965_CR19","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00467-018-3903-9","volume":"33","author":"L Percheron","year":"2018","unstructured":"Percheron L, Gramada R, Tellier S, Salomon R, Harambat J, Llanas B, Fila M, Allain-Launay E, Lapeyraque AL, Leroy V, Adra AL, Berard E, Bourdat-Michel G, Chehade H, Eckart P, Merieau E, Pietrement C, Sellier-Leclerc AL, Fremeaux-Bacchi V, Dimeglio C, Garnier A (2018) Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. Pediatr Nephrol 33:1385\u20131394. https:\/\/doi.org\/10.1007\/s00467-018-3903-9","journal-title":"Pediatr Nephrol"},{"key":"4965_CR20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","volume":"20","author":"S Jodele","year":"2014","unstructured":"Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM (2014) Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 20:518\u2013525. https:\/\/doi.org\/10.1016\/j.bbmt.2013.12.565","journal-title":"Biol Blood Marrow Transplant"},{"key":"4965_CR21","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.4081\/hr.2015.6107","volume":"7","author":"C Fernandez","year":"2015","unstructured":"Fernandez C, Lario A, Fores R, Cabrera R (2015) Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease. Hematol Rep 7:6107. https:\/\/doi.org\/10.4081\/hr.2015.6107","journal-title":"Hematol Rep"},{"key":"4965_CR22","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2215\/CJN.12901211","volume":"7","author":"AS Bomback","year":"2012","unstructured":"Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D\u2019Agati VD, Canetta PA, Radhakrishnan J, Appel GB (2012) Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7:748\u2013756. https:\/\/doi.org\/10.2215\/CJN.12901211","journal-title":"Clin J Am Soc Nephrol"},{"key":"4965_CR23","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1056\/NEJMc1112273","volume":"366","author":"E Daina","year":"2012","unstructured":"Daina E, Noris M, Remuzzi G (2012) Eculizumab in a patient with dense-deposit disease. N Engl J Med 366:1161\u20131163. https:\/\/doi.org\/10.1056\/NEJMc1112273","journal-title":"N Engl J Med"},{"key":"4965_CR24","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMc1111953","volume":"366","author":"M Vivarelli","year":"2012","unstructured":"Vivarelli M, Pasini A, Emma F (2012) Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366:1163\u20131165. https:\/\/doi.org\/10.1056\/NEJMc1111953","journal-title":"N Engl J Med"},{"key":"4965_CR25","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s00467-013-2503-y","volume":"28","author":"S Gurkan","year":"2013","unstructured":"Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ (2013) Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 28:1975\u20131981. https:\/\/doi.org\/10.1007\/s00467-013-2503-y","journal-title":"Pediatr Nephrol"},{"key":"4965_CR26","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00467-014-2839-y","volume":"29","author":"A Sanchez-Moreno","year":"2014","unstructured":"Sanchez-Moreno A, De la Cerda F, Cabrera R, Fijo J, Lopez-Trascasa M, Bedoya R, Rodriguez de Cordoba S, Ybot-Gonzalez P (2014) Eculizumab in dense-deposit disease after renal transplantation. Pediatr Nephrol 29:2055\u20132059. https:\/\/doi.org\/10.1007\/s00467-014-2839-y","journal-title":"Pediatr Nephrol"},{"key":"4965_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/ckj\/sfv044","volume":"8","author":"M Inman","year":"2015","unstructured":"Inman M, Prater G, Fatima H, Wallace E (2015) Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis. Clin Kidney J 8:445\u2013448. https:\/\/doi.org\/10.1093\/ckj\/sfv044","journal-title":"Clin Kidney J"},{"key":"4965_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","volume":"65","author":"M Le Quintrec","year":"2015","unstructured":"Le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M, Goujon JM, Fremeaux-Bacchi V, Fakhouri F (2015) Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 65:484\u2013489. https:\/\/doi.org\/10.1053\/j.ajkd.2014.09.025","journal-title":"Am J Kidney Dis"},{"key":"4965_CR29","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2215\/CJN.01360215","volume":"10","author":"MJ Oosterveld","year":"2015","unstructured":"Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, Amann K, Davin JC, Bouts AH, Schriemer PJ, Groothoff JW (2015) Eculizumab in pediatric dense deposit disease. Clin J Am Soc Nephrol 10:1773\u20131782. https:\/\/doi.org\/10.2215\/CJN.01360215","journal-title":"Clin J Am Soc Nephrol"},{"key":"4965_CR30","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00467-017-3619-2","volume":"32","author":"C Lebreton","year":"2017","unstructured":"Lebreton C, Bacchetta J, Dijoud F, Bessenay L, Fremeaux-Bacchi V, Sellier-Leclerc AL (2017) C3 glomerulopathy and eculizumab: a report on four paediatric cases. Pediatr Nephrol 32:1023\u20131028. https:\/\/doi.org\/10.1007\/s00467-017-3619-2","journal-title":"Pediatr Nephrol"},{"key":"4965_CR31","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00467-013-2748-5","volume":"29","author":"O Ozkaya","year":"2014","unstructured":"Ozkaya O, Nalcacioglu H, Tekcan D, Genc G, Meydan BC, Ozdemir BH, Baysal MK, Keceligil HT (2014) Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy. Pediatr Nephrol 29:1283\u20131287. https:\/\/doi.org\/10.1007\/s00467-013-2748-5","journal-title":"Pediatr Nephrol"},{"key":"4965_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","volume":"9","author":"JE Locke","year":"2009","unstructured":"Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, Stewart ZA, Warren DS, Zachary AA, Montgomery RA (2009) The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 9:231\u2013235. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02451.x","journal-title":"Am J Transplant"},{"key":"4965_CR33","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.transproceed.2012.09.038","volume":"44","author":"F Gonzalez-Roncero","year":"2012","unstructured":"Gonzalez-Roncero F, Suner M, Bernal G, Cabello V, Toro M, Pereira P, Angel Gentil M (2012) Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 44:2690\u20132694. https:\/\/doi.org\/10.1016\/j.transproceed.2012.09.038","journal-title":"Transplant Proc"},{"key":"4965_CR34","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1016\/j.transproceed.2012.03.053","volume":"44","author":"ZA Stewart","year":"2012","unstructured":"Stewart ZA, Collins TE, Schlueter AJ, Raife TI, Holanda DG, Nair R, Reed AI, Thomas CP (2012) Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc 44:3033\u20133036. https:\/\/doi.org\/10.1016\/j.transproceed.2012.03.053","journal-title":"Transplant Proc"},{"key":"4965_CR35","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.transproceed.2013.02.062","volume":"45","author":"B Kocak","year":"2013","unstructured":"Kocak B, Arpali E, Demiralp E, Yelken B, Karatas C, Gorcin S, Gorgulu N, Uzunalan M, Turkmen A, Kalayoglu M (2013) Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant Proc 45:1022\u20131025. https:\/\/doi.org\/10.1016\/j.transproceed.2013.02.062","journal-title":"Transplant Proc"},{"key":"4965_CR36","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.transproceed.2015.06.029","volume":"47","author":"B Yelken","year":"2015","unstructured":"Yelken B, Arpali E, Gorcin S, Kocak B, Karatas C, Demiralp E, Turkmen A (2015) Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience. Transplant Proc 47:1754\u20131759. https:\/\/doi.org\/10.1016\/j.transproceed.2015.06.029","journal-title":"Transplant Proc"},{"key":"4965_CR37","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/TP.0000000000000184","volume":"98","author":"M Burbach","year":"2014","unstructured":"Burbach M, Suberbielle C, Brocheriou I, Ridel C, Mesnard L, Dahan K, Rondeau E, Hertig A (2014) Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation 98:1056\u20131059. https:\/\/doi.org\/10.1097\/TP.0000000000000184","journal-title":"Transplantation"},{"key":"4965_CR38","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/petr.12187","volume":"18","author":"G Ghirardo","year":"2014","unstructured":"Ghirardo G, Benetti E, Poli F, Vidal E, Della Vella M, Cozzi E, Murer L (2014) Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody. Pediatr Transplant 18:E1\u2013E5. https:\/\/doi.org\/10.1111\/petr.12187","journal-title":"Pediatr Transplant"},{"key":"4965_CR39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/TP.0000000000000298","volume":"98","author":"BJ Orandi","year":"2014","unstructured":"Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, Montgomery RA (2014) Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 98:857\u2013863. https:\/\/doi.org\/10.1097\/TP.0000000000000298","journal-title":"Transplantation"},{"key":"4965_CR40","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00467-013-2711-5","volume":"29","author":"C Rousset-Rouviere","year":"2014","unstructured":"Rousset-Rouviere C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M (2014) Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 29:1107\u20131111. https:\/\/doi.org\/10.1007\/s00467-013-2711-5","journal-title":"Pediatr Nephrol"},{"key":"4965_CR41","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1542\/peds.2014-2275","volume":"135","author":"H Chehade","year":"2015","unstructured":"Chehade H, Rotman S, Matter M, Girardin E, Aubert V, Pascual M (2015) Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient. Pediatrics 135:e551\u2013e555. https:\/\/doi.org\/10.1542\/peds.2014-2275","journal-title":"Pediatrics"},{"key":"4965_CR42","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.transproceed.2016.03.028","volume":"48","author":"B Smith","year":"2016","unstructured":"Smith B, Kumar V, Mompoint-Williams D, Reed RD, MacLennan PA, Stegner K, Locke JE (2016) Dosing eculizumab for antibody-mediated rejection in kidney transplantation: a case report. Transplant Proc 48:3099\u20133105. https:\/\/doi.org\/10.1016\/j.transproceed.2016.03.028","journal-title":"Transplant Proc"},{"key":"4965_CR43","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00467-015-3306-0","volume":"31","author":"CL Tran","year":"2016","unstructured":"Tran CL, Sethi S, Murray D, Cramer CH, Sas DJ, Willrich M, Smith RJ, Fervenza FC (2016) Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Pediatr Nephrol 31:683\u2013687. https:\/\/doi.org\/10.1007\/s00467-015-3306-0","journal-title":"Pediatr Nephrol"},{"key":"4965_CR44","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrneph.2012.212","volume":"8","author":"MD Stegall","year":"2012","unstructured":"Stegall MD, Chedid MF, Cornell LD (2012) The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 8:670\u2013678. https:\/\/doi.org\/10.1038\/nrneph.2012.212","journal-title":"Nat Rev Nephrol"},{"key":"4965_CR45","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2215\/CJN.01640309","volume":"4","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Work DF (2009) Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4:1832\u20131843. https:\/\/doi.org\/10.2215\/CJN.01640309","journal-title":"Clin J Am Soc Nephrol"},{"key":"4965_CR46","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"key":"4965_CR47","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1053\/j.ajkd.2018.04.021","volume":"72","author":"SH Saydah","year":"2018","unstructured":"Saydah SH, Xie H, Imperatore G, Burrows NR, Pavkov ME (2018) Trends in albuminuria and GFR among adolescents in the United States, 1988-2014. Am J Kidney Dis 72:644\u2013652. https:\/\/doi.org\/10.1053\/j.ajkd.2018.04.021","journal-title":"Am J Kidney Dis"},{"key":"4965_CR48","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00228-016-2027-z","volume":"72","author":"J Castaneda-Sanabria","year":"2016","unstructured":"Castaneda-Sanabria J, Hajage D, Le Jouan M, Perozziello A, Tubach F (2016) Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field. Eur J Clin Pharmacol 72:737\u2013746. https:\/\/doi.org\/10.1007\/s00228-016-2027-z","journal-title":"Eur J Clin Pharmacol"},{"key":"4965_CR49","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701\u2013711. https:\/\/doi.org\/10.1016\/j.kint.2015.11.026","journal-title":"Kidney Int"},{"key":"4965_CR50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","volume":"20","author":"J Menne","year":"2019","unstructured":"Menne J, Delmas Y, Fakhouri F, Licht C, Lommele A, Minetti EE, Provot F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA (2019) Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol 20:125. https:\/\/doi.org\/10.1186\/s12882-019-1314-1","journal-title":"BMC Nephrol"},{"key":"4965_CR51","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061\u20131073. https:\/\/doi.org\/10.1038\/ki.2014.423","journal-title":"Kidney Int"},{"key":"4965_CR52","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10157-018-1610-2","volume":"23","author":"S Ito","year":"2019","unstructured":"Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S (2019) Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol 23:112\u2013121. https:\/\/doi.org\/10.1007\/s10157-018-1610-2","journal-title":"Clin Exp Nephrol"},{"key":"4965_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","volume":"12","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Fila M, Provot F, Delmas Y, Barbet C, Chatelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Fremeaux-Bacchi V (2017) Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol 12:50\u201359. https:\/\/doi.org\/10.2215\/CJN.06440616","journal-title":"Clin J Am Soc Nephrol"},{"key":"4965_CR54","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12879-016-1627-7","volume":"16","author":"GR Jenssen","year":"2016","unstructured":"Jenssen GR, Vold L, Hovland E, Bangstad HJ, Nygard K, Bjerre A (2016) Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999 to 2008. BMC Infect Dis 16:285. https:\/\/doi.org\/10.1186\/s12879-016-1627-7","journal-title":"BMC Infect Dis"},{"key":"4965_CR55","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fped.2018.00220","volume":"6","author":"L Vaterodt","year":"2018","unstructured":"Vaterodt L, Holle J, Huseman D, Muller D, Thumfart J (2018) Short- and long-term renal outcome of hemolytic-uremic syndrome in childhood. Front Pediatr 6:220. https:\/\/doi.org\/10.3389\/fped.2018.00220","journal-title":"Front Pediatr"},{"key":"4965_CR56","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jpeds.2014.12.064","volume":"166","author":"RK Mody","year":"2015","unstructured":"Mody RK, Gu W, Griffin PM, Jones TF, Rounds J, Shiferaw B, Tobin-D\u2019Angelo M, Smith G, Spina N, Hurd S, Lathrop S, Palmer A, Boothe E, Luna-Gierke RE, Hoekstra RM (2015) Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr 166:1022\u20131029. https:\/\/doi.org\/10.1016\/j.jpeds.2014.12.064","journal-title":"J Pediatr"},{"key":"4965_CR57","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/cid\/cis196","volume":"54","author":"A Rosales","year":"2012","unstructured":"Rosales A, Hofer J, Zimmerhackl LB, Jungraithmayr TC, Riedl M, Giner T, Strasak A, Orth-Holler D, Wurzner R, Karch H, German-Austrian HUS Study Group (2012) Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 54:1413\u20131421. https:\/\/doi.org\/10.1093\/cid\/cis196","journal-title":"Clin Infect Dis"},{"key":"4965_CR58","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","volume":"4","author":"E Rondeau","year":"2019","unstructured":"Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D (2019) eculizumab safety: five-year experience from the global atypical hemolytic uremic syndrome registry. Kidney Int Rep 4:1568\u20131576. https:\/\/doi.org\/10.1016\/j.ekir.2019.07.016","journal-title":"Kidney Int Rep"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-04965-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-04965-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-04965-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T09:44:14Z","timestamp":1625564654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-04965-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4965"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-04965-5","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"26 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IRB approval was obtained at all participating centers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This was a retrospective study, and no participant consent was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Carla Nester is a member of the Alexion advisory board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}